SenesTech, Inc.
SenesTech develops and commercializes fertility-control products for managing rat and mouse populations. Its products are ContraPest, Evolve Rat, and Evolve Mouse. Evolve Rat, a soft bait containing cottonseed oil that reduces fertility in male and female rats, is its primary revenue-generating product. Evolve Mouse uses modified soft-bait technology with the same active ingredient to limit reproduction in mice. ContraPest is a liquid bait containing VCD and triptolide that targets rat fertility. Elevate Bait System is a hanging dispenser for ContraPest designed for roof rat habitats and hard-to-reach areas. SenesTech sells through channels that include agribusiness, pest management, industrial, retail, international, and e-commerce markets, and markets Evolve internationally through distributors. Its products are intended for use as part of integrated pest management programs. SenesTech’s corporate headquarters and manufacturing site are in Surprise, Arizona.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
SenesTech reported Q3 2026 revenue growth of 59% year-over-year and 42% sequentially, with gross profit reaching $796,000. The company attributed the increase to expansion in e-commerce and subscriptions.
SenesTech, Inc. (SNES) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SenesTech Reports Record Q3 2026 Revenue with 59% Year-Over-Year Growth Revenue increased 42% sequentially as e-commerce and subscriptions expanded; Gross profit reached a record $796,000 SURPRISE, Ariz., November 10, 2026 (GLOBE NEWSWIRE) — SenesTech, Inc. (NASDAQ:
SenesTech (NASDAQ: SNES) announced its Evolve® rodent birth-control products are now available through Walmart Fulfillment Services, enabling faster delivery and seven-day shipping. This partnership aims to increase product visibility and reduce fulfillment costs, contributing to the company's e-commerce growth.
Over the past 7 days, AlphAI's AI scored 11 news stories mentioning SNES (SenesTech, Inc.). Coverage has skewed bullish: 3 bullish, 7 neutral, and 1 bearish.
Recent SNES coverage spans financial news, insider activity and earnings.
In the last 30 days, SNES insiders filed 7 SEC Form 4 transactions — 7 purchases ($483K) and no sales. The most active reporter was GLENBROOK CAPITAL MANAGEMENT with 7 filings.
Strong top‑line growth likely supports a price rally.
Earnings beat on revenue and gross profit but net loss widened; investors may view growth positively.
Positive impact expected from faster, seven‑day shipping and broader Walmart.com reach.
Small insider purchase may create modest buying pressure.
Activist stake disclosure may prompt board and management changes, creating upside potential.
AlphAI scores every news story that mentions SNES with an AI model for sentiment and relevance, and aggregates insider trades from SenesTech, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
SenesTech reported Q3 2026 revenue growth of 59% year-over-year and 42% sequentially, with gross profit reaching $796,000. The company attributed the increase to expansion in e-commerce and subscriptions.
SenesTech, Inc. (SNES) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SenesTech Reports Record Q3 2026 Revenue with 59% Year-Over-Year Growth Revenue increased 42% sequentially as e-commerce and subscriptions expanded; Gross profit reached a record $796,000 SURPRISE, Ariz., November 10, 2026 (GLOBE NEWSWIRE) — SenesTech, Inc. (NASDAQ:
SenesTech (NASDAQ: SNES) announced its Evolve® rodent birth-control products are now available through Walmart Fulfillment Services, enabling faster delivery and seven-day shipping. This partnership aims to increase product visibility and reduce fulfillment costs, contributing to the company's e-commerce growth.
GLENBROOK CAPITAL MANAGEMENT purchased 30,000 indirectly-held shares of SenesTech, Inc. (SNES) at an average of $0.97 ($0.97–$1.02) across 2 trades over 2026-10-28 to 2026-10-30.
Justin LeBeau disclosed a 5.4% stake in SenesTech, Inc., totaling 294,773 shares. He believes the stock is undervalued and wants the company to control costs and avoid dilutive share offerings. LeBeau also supports some recommendations from Glenbrook Capital Management, including performance-based executive pay. He may discuss company matters with SenesTech leaders or other stockholders.
GLENBROOK CAPITAL MANAGEMENT purchased 103,875 indirectly-held shares of SenesTech, Inc. (SNES) at an average of $0.72 ($0.67–$0.80) across 3 trades over 2026-10-20 to 2026-10-22.
SenesTech, Inc. (SNES) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 SenesTech Receives Nasdaq Minimum Bid Price Notification and Highlights Record Third Quarter Revenue SURPRISE, Ariz., Oct. 22, 2026 — SenesTech, Inc. (NASDAQ: SNES), the leader in rodent birth control and sustainable rodent population management, today announced that
SenesTech reported preliminary Q3 revenue of $1.1 million, a quarterly record. The company received a Nasdaq notice for its stock price falling below $1, with 180 days to comply. SenesTech plans to address this while continuing operations and evaluating financing options. The stock continues to trade under the symbol SNES.
Glenbrook Capital bought $706,056 in SenesTech (SNES) shares at $0.63-$0.89. Applied Digital (APLD) insiders bought $6.7M shares at $18.04-$18.86. Wayfair (W) insiders sold $26M shares at $110-$112.92. Talos (TALO) and Aflac (AFL) also saw insider sales.
GLENBROOK CAPITAL MANAGEMENT purchased 983,804 indirectly-held shares of SenesTech, Inc. (SNES) at an average of $0.72 ($0.63–$0.77, $0.71M total) across 3 trades over 2026-10-15 to 2026-10-19.
